Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Johnson and Johnson
Medtronic
Dow
Merck

Last Updated: November 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,840,684

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,840,684 protect, and when does it expire?

Patent 5,840,684 protects ORBACTIV and is included in one NDA.

This patent has sixty-nine patent family members in thirty countries.

Summary for Patent: 5,840,684
Title: Glycopeptide antibiotic derivatives
Abstract:The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
Inventor(s): Cooper; Robin D. G. (Indianapolis, IN), Huff; Bret E. (Mooresville, IN), Nicas; Thalia I. (Indianapolis, IN), Quatroche; John T. (Indianapolis, IN), Rodriguez; Michael J. (Indianapolis, IN), Snyder; Nancy J. (Charlottesville, IN), Staszak; Michael A. (Indianapolis, IN), Thompson; Richard C. (Frankfort, IN), Wilkie; Stephen C. (Indianapolis, IN), Zweifel; Mark J. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:08/410,155
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Drugs Protected by US Patent 5,840,684

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 5,840,684

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 248856   Start Trial
Austria 253077   Start Trial
Austria 266042   Start Trial
Austria 349464   Start Trial
Australia 1138995   Start Trial
Australia 5312196   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Merck
Colorcon
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.